AGREEMENT AND PLAN OF MERGER by and among REATA PHARMACEUTICALS, INC., BIOGEN INC. and RIVER ACQUISITION, INC. Dated as of July 28, 2023Agreement and Plan of Merger • July 31st, 2023 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of July 28, 2023, by and among Biogen Inc., a Delaware corporation (“Parent”), River Acquisition, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”).
Reata Pharmaceuticals, Inc. 5,500,000 Shares Class A Common Stock ($0.001 par value per share) Underwriting AgreementUnderwriting Agreement • May 26th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
Reata Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 5,500,000 shares of Class A common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 825,000 additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either
AMENDED AND RESTATED LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 14th, 2018 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of June 14, 2018 (the “Effective Date”) by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), and REATA PHARMACEUTICALS, INC., a Delaware corporation with offices located at 2801 Gateway Drive, Suite 150, Irving, TX 75063 (“Borrower”), amends and restates in its entirety that certain Loan and Security Agreement dated as of March 31, 2017 by and amo
Reata Pharmaceuticals, Inc. 3,000,000 Shares Class A Common Stock ($0.001 par value per share) Underwriting AgreementReata Pharmaceuticals Inc • July 26th, 2018 • Pharmaceutical preparations • New York
Reata Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated (together, the “Representatives”) are acting as representatives, 3,000,000 shares of Class A common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 450,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the
AT-THE-MARKET EQUITY OFFERING SALES AGREEMENTTerms Agreement • November 13th, 2017 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Stifel, Nicolaus & Company, Incorporated (“Stifel Nicolaus”), as sales agent and/or principal (“Agent”), shares (the “Shares”) of the Company’s Class A common stock, $0.001 par value per share (the “Common Stock”), having an aggregate offering price of up to $50,000,000 on the terms set forth in Section 2 of this At-The-Market Equity Offering Sales Agreement (the “Agreement”). The Company agrees that whenever it determines to sell Shares directly to the Agent as principal, it will enter into a separate agreement (each, a “Terms Agreement”) in substantially the form of Annex I hereto, relating to such sale in accordance with Section 3 of this Agreement.
REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • August 8th, 2023 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Agreement (“Agreement”) is made and entered into as of the _12th__ day of _June__, 2023, by and between Reata Pharmaceuticals, a Delaware corporation (the “Company”), and Rajiv Patni (“Indemnitee”).
Reata Pharmaceuticals, Inc. 2,000,000 Shares Class A Common Stock ($0.001 par value per share) Underwriting AgreementUnderwriting Agreement • December 3rd, 2020 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
Reata Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule III hereto (the “Underwriters”), for whom Barclays Capital Inc. and Goldman Sachs & Co. LLC (the “Representatives”) are acting as representatives, 2,000,000 shares of Class A common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 300,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule III other than you, the term Representatives as used herein shall mean you, as Underwriter, and the terms Representatives and Underwriters s
EMPLOYMENT AGREEMENT by and between Reata Pharmaceuticals, Inc. and Rajiv PatniEmployment Agreement • August 8th, 2023 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Texas
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of June 12, 2023 by and between Reata Pharmaceuticals, Inc., a Delaware corporation (together with its successors and assigns permitted hereunder, the “Company”), and Rajiv Patni (the “Executive”).
LOAN AGREEMENT Dated as of May 5, 2023 among REATA PHARMACEUTICALS, INC. (as Borrower, and a Credit Party), THE GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit Parties), BIOPHARMA CREDIT PLC (as Collateral...Loan Agreement • May 10th, 2023 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
THIS LOAN AGREEMENT (this “Agreement”), dated as of May 5, 2023 (the “Effective Date”) by and among REATA PHARMACEUTICALS, INC., a Delaware corporation (as “Borrower” and a Credit Party), the Guarantors signatory hereto or otherwise party hereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows:
VOTING AND SUPPORT AGREEMENTVoting and Support Agreement • July 31st, 2023 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS VOTING AND SUPPORT AGREEMENT is dated as of July 28, 2023 (this “Agreement”), by and among each stockholder of Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), set forth on Exhibit A hereto (each a “Holder” and collectively the “Holders”), Biogen Inc., a Delaware corporation (“Parent”), and River Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”).
EXCLUSIVE LICENSE AGREEMENT between Reata Pharmaceuticals, Inc. and KU Center for Technology Commercialization, Inc.License Agreement • January 4th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Kansas
THIS LICENSE Agreement (“Agreement”) is entered into this 26th day of September, 2014 by and between the KU CENTER FOR TECHNOLOGY COMMERCIALIZATION, INC, a Kansas non-profit § 501(c)(3) corporation, having its principal place of business at 3901 Rainbow Boulevard, Kansas City, Kansas 66160, hereinafter referred to as “KUCTC” or “Licensor,” and “REATA PHARMACEUTICALS, INC.” having its principal place of business at 2801 Gateway Drive, Suite 150, Irving, Texas 75063, hereinafter referred to as “Licensee.”
REATA PHARMACEUTICALS, INC. EIGHTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 4th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Texas
This EIGHTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of the 6th day of December, 2011, by and among REATA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), the parties listed on the signature pages hereto, the Investors (as defined herein) listed on Schedule A hereto, University of Texas System (“UT System”), and the stockholders of the Company listed on Schedule B hereto (the “Other Stockholders”).
ContractLicense Agreement • February 8th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS [***]. AN UNREDACTED VERSION OF THIS EXHIBIT HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXCLUSIVE LICENSE and SUPPLY AGREEMENT by and between REATA PHARMACEUTICALS, INC. and KYOWA HAKKO KIRIN CO. LTD.Supply Agreement • January 4th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Exclusive License and Supply Agreement (this “Agreement”) effective as of December 24, 2009 (the “Effective Date”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
COLLABORATION AGREEMENT between REATA PHARMACEUTICALS, INC. and ABBOTT PHARMACEUTICALS PR LTD. Dated as of December 9, 2011Collaboration Agreement • February 8th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS COLLABORATION AGREEMENT (this “Agreement”) is entered into as of December 9, 2011 (the “Effective Date”) by and between REATA PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and ABBOTT PHARMACEUTICALS PR LTD., a Bermuda corporation having its principal place of business at 2 KM 58.2, Cruce Davila, Barceloneta 00617, Puerto Rico (“Abbott”). Reata and Abbott are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
SEVENTH SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study in JapanExclusive License and Supply Agreement • August 8th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Seventh Supplement (herein so called), effective as of February 28, 2022 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement”), is by and between Reata Pharmaceuticals Holdings, LLC, a limited liability company organized and existing under the laws of Delaware, USA, with an address at 5320 Legacy Drive, Plano, Texas 75024 (“Reata”), as assignee of the Original Agreement from Reata Pharmaceuticals, Inc., a Delaware corporation and the original signatory to the Original Agreement, as assignor (“Reata Pharmaceuticals”), and Kyowa Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.
LEASE SDCO GATEWAY COMMERCE I & II, INC., Landlord, and REATA PHARMACEUTICALS, INC., TenantCommencement Date Agreement • January 4th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
By this Lease Landlord leases to Tenant and Tenant leases from Landlord the Premises in the Building as set forth and described on the Reference Pages. The Premises are depicted on the floor plan attached hereto as Exhibit A, and the Building is depicted on the site plan attached hereto as Exhibit A-1. The Reference Pages, including all terms defined thereon, are incorporated as part of this Lease.
VOTING AND SUPPORT AGREEMENTVoting and Support Agreement • July 31st, 2023 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS VOTING AND SUPPORT AGREEMENT is dated as of July 28, 2023 (this “Agreement”), by and among each stockholder of Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), set forth on Exhibit A hereto (each a “Holder” and collectively the “Holders”), Biogen Inc., a Delaware corporation (“Parent”), and River Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”).
AMENDED AND RESTATED LICENSE AGREEMENT betweenLicense Agreement • October 10th, 2019 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].
SECOND AMENDMENT TO LEASE AGREEMENTLease Agreement • August 8th, 2023 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
LEASE AMENDMENT NO. 13Reata Pharmaceuticals Inc • February 28th, 2022 • Pharmaceutical preparations
THIS LEASE AMENDMENT NO. 13 (this “Amendment”) is made and entered into effective as of February 4, 2022 (the “Effective Date”) by and between SDCO GATEWAY COMMERCE I & II, INC., a Delaware corporation (“Landlord”), and REATA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
SECOND SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • June 23rd, 2017 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Second Supplement (herein so called), effective as of March 21, 2017 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 10th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Kansas
This Amendment No. 1 (this “Amendment #1”) to the Exclusive License Agreement, dated as of September 26, 2014 (the “License Agreement”), by and between the KU CENTER FOR TECHNOLOGY COMMERCIALIZATION, INC., a Kansas non-profit §501 (c)(3) corporation, having its principal place of business at 3901 Rainbow Boulevard, Kansas City, Kansas 66160 (“KUCTC” or “Licensor”), and REATA PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business located at 5320 Legacy Drive, Plano, Texas 75024 (“REATA” or “Licensee”), is entered into as of the date of the last signature below (the “Effective Date of Amendment #1”).
ContractPatent License Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
Specific terms in this Exhibit have been redacted because such terms are both not material and are of the type that the Company treats as private or confidential. These redacted terms have been marked in this Exhibit with three asterisks [***].
FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENTLoan and Security Agreement • October 10th, 2019 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT to Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into as of October 9, 2019, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), and REATA PHARMACEUTICALS, INC., a Delaware corporation with offices located at 2801 Gateway Drive, Suite 150, Irving, TX 75063 (“Borrower”).
EXCLUSIVE PATENT LICENSE AGREEMENT AMONG THE UNIVERSITY OF TEXAS DARTMOUTH COLLEGE AND REATA DISCOVERY, INC.Patent License Agreement • January 4th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Texas
THIS Agreement (“AGREEMENT”) is made on this 15th day of July, 2004, by and among the Board of Regents (the “BOARD”) of The University of Texas System (the “SYSTEM”), an agency of the State of Texas, whose address is 201West 7th Street, Austin, Texas 78701, on behalf of the University of Texas M. D. Anderson Cancer Center (‘‘UTMDACC”), a component institution of the SYSTEM, Trustees of Dartmouth College (“DARTMOUTH”), a non-profit educational and research institution existing under the laws of the State of New Hampshire, and being located at Hanover, New Hampshire (BOARD, UTMDACC and DARTMOUTH collectively “LICENSORS”), and Reata Discovery, Inc. (“LICENSEE”), a Delaware corporation having a principal place of business located at 1950 N. Stemmons Freeway, Suite 5001, Dallas, Texas 75207.
EXPANSION AGREEMENTExpansion Agreement • October 16th, 2019 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Texas
THIS EXPANSION AGREEMENT (this “Agreement”) dated as of October 15, 2019 (the “Effective Date”), is made and executed by TC LEGACY LAND VENTURE, LLC, a Delaware limited liability company (“Owner”), and REATA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
TERMINATION OF EXPANSION AGREEMENTTermination of Expansion Agreement • August 8th, 2023 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
THIS TERMINATION OF EXPANSION AGREEMENT (this “Termination”) is executed by TC LEGACY LAND VENTURE, LLC, a Delaware limited liability company (“Owner”), and REATA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
AMENDMENT NO. 1 TO SUBLEASE AGREEMENTTo Sublease Agreement • February 19th, 2020 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Texas
This Amendment No. 1 to Sublease Agreement (this “Amendment”) is executed as of December 12, 2019, between DENBURY ONSHORE, LLC, a Delaware limited liability company (“Denbury”), and REATA PHARMACEUTICALS, INC., a Delaware corporation (“Subtenant”).
COLLABORATION AGREEMENT between REATA PHARMACEUTICALS, INC. and ABBOTT PHARMACEUTICALS PR LTD. Dated as of December 9, 2011Collaboration Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
Specific terms in this Exhibit have been redacted because such terms are both not material and are of the type that the Company treats as private or confidential. These redacted terms have been marked in this Exhibit with three asterisks [***].
SIXTH SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • August 22nd, 2019 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Sixth Supplement (herein so called), effective as of August 22, 2019 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.
AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION FUNDING AGREEMENTDevelopment and Commercialization Funding Agreement • May 10th, 2023 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Amended and Restated Development and Commercialization Funding Agreement (this “Agreement”), made effective as of May 4, 2023 (the “Effective Date”), is by and between Reata Pharmaceuticals Inc., a Delaware corporation (“Reata”), and BXLS V – River L.P. (together with its successors and assigns, “BXLS”), a limited partnership organized and existing under the laws of Delaware (each, a “Party” and collectively, the “Parties”).
AMENDMENT NO. 2 TO 2009 LICENSE AGREEMENT2009 License Agreement • November 8th, 2021 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Amendment No. 2, dated as of August 17, 2021 (this “Amendment”), to the Reata Pharmaceuticals, Inc. - Dartmouth Exclusive License Agreement, effective December 16, 2009, as amended by the Amendment No. 1 to 2009 License Agreement dated as of July 9, 2012 (as so amended, the “License Agreement”), by and between Trustees of Dartmouth College (“DARTMOUTH”), said college being a non-profit educational and research institution existing under the laws of the State of New Hampshire, Hanover, New Hampshire 03755, and Reata Pharmaceuticals, Inc. (“REATA”), a Delaware corporation having a principal place of business located at 5320 Legacy Drive, Plano, Texas 75024.
THIRD SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study (Alport Syndrome) in JapanExclusive License and Supply Agreement • December 7th, 2017 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Third Supplement (herein so called), effective as of December 6, 2017 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.
DEVELOPMENT AND COMMERCIALIZATION FUNDING AGREEMENTDevelopment and Commercialization Funding Agreement • August 10th, 2020 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Development and Commercialization Funding Agreement (“Agreement”), made effective as of June 10, 2020 (the “Effective Date”), is by and between Reata Pharmaceuticals Inc., a Delaware corporation (“Reata”), and BXLS V – River L.P. (together with its successors and assigns, “BXLS”), a limited partnership organized and existing under the laws of Delaware (each, a “Party” and collectively, the “Parties”).
